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Background
The comparison of gadofosveset (Ablavar, Lantheus Medi-
cal) at a dose of 0.06 mmol /kg with gadopentetate dime-
glumine (Magnevist, Bayer-Schering Inc.) at a dose of
0.2 mmol /kg for CEMRA in pediatric patients with com-
plex congenital heart disease (CCHD) at 1.5T and 3.0T.
Methods
Twenty-eight pediatric patients with CCHD underwent
CEMRA at 3.0T (n=16) or at 1.5T (n=12). Sixteen patients
were imaged with gadofosveset; 9 at 3.0T (age 1.00 ± 1.58
months; weight 2.38 ± 1.13 kg) and 7 at 1.5T (age 8.00 ±
7.83 months; weight 5.06 ± 3.09 kg). Twelve patients were
imaged with gadopentetate; 7 at 3.0T (age 1.00 ± 1.41
months; weight 3.02 ± 1.59 kg) and 5 at 1.5T (age 6.60 ±
8.62 months; weight 5.23 ± 2.93 kg). High resolution
CEMRA was performed in two phases with strictly com-
parable imaging parameters, acquisition times and con-
trast agent infusion periods. Two independent observers
scored the studies blindly on a four point scale for image
quality, artifacts and vessel definition.
Results
At 3.0T, overall image quality (IQ) was good to excel-
lent (3<=IQ<=4) in all patients and similar for gadofos-
veset and gadopentate. At 1.5T, IQ was also good to
excellent, but higher for gadofosveset than gadopente-
tate. Cardiac motion or pulsation artifact was found in
all studies at both field strengths but appeared more
severe at 3.0T than 1.5T. Parallel acquisition artifact was
noted in all studies at 3.0T, but in no studies at 1.5T.
Vessel definition scores were higher for gadofosveset at
both field strengths and both contrast phases, but lower
for gadopentetate in the venous phase at 3.0T and in
both phases at 1.5T. SNR and CNR was higher at 3.0T
than 1.5T in the aortic arch, pulmonary artery, inferior
vena cava and superior vena cava. SNR and CNR was
higher for gadofosveset than gadopentetate during the
arterial phase in the aortic arch and pulmonary artery.
Conclusions
Both gadofosveset and gadopentetate support reliable and
high quality CEMRA at 1.5T and 3.0T in children with
complex congenital vascular diseases. However, gadofosve-
set scored higher than gadopentetate with respect to
image quality, vessel definition, SNR and CNR at less than
one third the dose of Gadolinium. Furthermore, the pro-
longed intravascular residence time of gadofosveset
enabled the maximum duration of breath holding to be
halved relative to gadopentetate, while maintaining excel-
lent enhancement in the venous phase.
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Figure 1 3D volume rendered reconstruction in a 4 day old neonate with interrupted aortic arch.
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